Amicus Therapeutics, Inc. Stock News

V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al. V.O.S. Selections, Inc.; Plastic Services and Products, LCC, d/b/a Genova Pipe; MicroKits, LCC; FishUSA Inc.; Terry Precision Cycling LLC v. President Donald J. Trump, et al.

PRINCETON, N.J., Aug. 29, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in September.

SEATTLE--(BUSINESS WIRE)--A coalition of American Jewish organizations have filed an amicus brief in the United States Court of Appeals for the Second Circuit in support of a Vermont federal court's consideration of Rümeysa Öztürk's habeas petition objecting to her then-detention. Öztürk, a Turkish national and PhD student at Tufts University, was detained this spring and held in an ICE facilit...

People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al. People of the State of New York, by Attorney General Letitia James v. Donald J. Trump, et al.

Physicians file amicus brief opposing removal of religious exemptions to vaccines. Objections include components derived from pork or aborted fetal tissue.

Amicus (FOLD) Q2 Revenue Jumps 22%

Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA, targeting $1 billion in revenue by 2028. The DMX-200 licensing deal opens a major market opportunity in FSGS, with positive interim phase 3 data and potential for broader rare renal indications. Financially, Amicus has limited cash but can raise more through its ATM facility, and its approved ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley L. Campbell - CEO, President & Director Jeffrey P.